Etik Mardliyati

Etik Mardliyati

*This is an algorithmically generated author record based on publicly available information.

Etik Mardliyati has a total of 73 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • High-Protein Enhancement of Spirulina via CO 2 Nanobubble Cultivation and Post-Harvest Mechanical Milling: Biochemical and Environmental Insights

    by Ande Fudja Rafryanto, Yasinta Rahmatul Putri, Muhammad Miftah Jauhar, Putri Hawa Syaifie, Mita Fitriani, Raden Ayu Nurul Khotimah, Marsiti Apriastini, Dwi Susilaningsih, Arramel, Etik Mardliyati, et al.

    In recent years, Spirulina platensis has gained attention as a sustainable microalga for protein, pigment, lipid, and bioactive compound production. This study integrates upstream and downstream optimization through (i) pre-cultivation CO2 nanobubbles (CO2-NBs) to enhance inorganic carbon delivery and (ii) post-harvest mechanical milling for biomass refinement. Biochemical integrity was evaluated using Raman spectroscopy, Fourier-transform infrared (FTIR) spectroscopy, and proximate analysis. Meanwhile, CO2-NBs characteristics, including size and zeta potential, were assessed in an aquadest medium. Pre-cultivation with CO2-NBs significantly enhanced protein content from 5.21 to 32.3% on a dry-weight basis following 30 min of injection. This improvement was supported by the intensified Raman shift around 1005 cm−1, associated with phenylalanine, alongside FTIR peaks near 1650 and 1050 cm−1, confirmed amide I and II as protein indicators. Post-mechanical milling of CO2-NBs with 30 min of injection time effectively reduced dry cell weight (DCW) S. platensis size from 1009 to 395−566.2 nm. Life cycle assessment (LCA) limited to cultivation highlighted the environmental advantage of CO2-NBs, reducing emissions to 473.9 kg CO2e/kg dry weight relative to 713.1 kg CO2e/kg in the control.

  • Identification of Homotrigona apicalis propolis compounds as α-glucosidase inhibitors with antidiabetic activity in a molecular docking approach

    by Paula Mariana Kustiawan, Kafka Navisa Suwarno, Vera Herliani Pratiwi, Khalish Arsy Al Khairy Siregar, Nunung Herlina, Ghozali Ghozali, Putri Hawa Syaifie, Etik Mardliyanti


  • A recent study of natural hydrogels: improving mechanical properties for biomedical applications

    by Atharva Shukla, Putri Hawa Syaifie, Nurul Taufiqu Rochman, Syahnanda Jaya Syaifullah, Muhammad Miftah Jauhar, Etik Mardliyati

    Natural polymer-based hydrogels, generally composed of hydrophilic polymers capable of absorbing large amounts of water, have garnered attention for biomedical applications because of their biocompatibility, biodegradability, and eco-friendliness. Natural polymer-based hydrogels derived from alginate, starch, cellulose, and chitosan are particularly valuable in fields such as drug delivery, wound dressing, and tissue engineering. However, compared with synthetic hydrogels, their poor mechanical properties limit their use in load-bearing applications. This review explores recent advancements in the enhancement of the mechanical strength of natural hydrogels while maintaining their biocompatibility for biomedical applications. Strategies such as chemical modification, blending with stronger materials, and optimized cross-linking are discussed. By improving their mechanical resilience, natural hydrogels can become more suitable for demanding biomedical applications, like tissue scaffolding and cartilage repair. Additionally, this review identifies the ongoing challenges and future directions for maximizing the potential of natural polymer-based hydrogels in advanced medical therapies.


  • Open Access

    Recent updates in applications of nanomedicine for the treatment of hepatic fibrosis

    by Damai Ria Setyawati, Fransiska Christydira Sekaringtyas, Riyona Desvy Pratiwi, A’lIyatur Rosyidah, Rohimmahtunnissa Azhar, Nunik Gustini, Gita Syahputra, Idah Rosidah, Etik Mardliyati, Tarwadi, et al.

    Over recent decades, nanomedicine has played an important role in the enhancement of therapeutic outcomes compared to those of conventional therapy. At the same time, nanoparticle drug delivery systems offer a significant reduction in side effects of treatments by lowering the off-target biodistribution of the active pharmaceutical ingredients. Cancer nanomedicine represents the most extensively studied nanotechnology application in the field of pharmaceutics and pharmacology since the first nanodrug for cancer treatment, liposomal doxorubicin (Doxil®), has been approved by the FDA. The advancement of cancer nanomedicine and its enormous technological success also included various other target diseases, including hepatic fibrosis. This confirms the versatility of nanomedicine for improving therapeutic activity. In this review, we summarize recent updates of nanomedicine platforms for improving therapeutic efficacy regarding liver fibrosis. We first emphasize the challenges of conventional drugs for penetrating the biological barriers of the liver. After that, we highlight design principles of nanocarriers for achieving improved drug delivery of antifibrosis drugs through passive and active targeting strategies.


  • Box-Behnken design assisted approach in optimizing lipid composition for cationic liposome formulation as gene carrier

    by Damai Ria Setyawati, Khairunnisa Azzahra, Etik Mardliyati, Tarwadi, Bismi Yasinta Maharani, Nurmeilis


  • Open Access

    Uncovering the anti-breast cancer activity potential of east Kalimantan propolis by In vitro and bioinformatics analysis

    by Paula Mariana Kustiawan, Khalish Arsy Al Khairy Siregar, Putri Hawa Syaifie, Fauzan Zein Muttaqin, Delfritama Ibadillah, Muhammad Miftah Jauhar, Nailulkamal Djamas, Etik Mardliyati, Nurul Taufiqu Rochman


  • Open Access

    Activity of propolis compounds as potential MMP1 and MMP2 inhibitors by in silico studies in wound healing application

    by Adzani Gaisani Arda, Putri Hawa Syaifie, Donny Ramadhan, Muhammad Miftah Jauhar, Dwi Wahyu Nugroho, Nofa Mardia Ningsih Kaswati, Alfian Noviyanto, Mega Safihtri, Nurul Taufiqu Rochman, Dimas Andrianto, et al.

    Context: Matrix metalloproteinases (MMPs) play a critical role in wound healing, with higher levels seen in chronic wounds, delaying healing. Since ancient times, propolis has been widely used for traditional wound healing. However, there is still limited research on MMP1 and MMP12. Aims: To evaluate new candidates of propolis compounds for targeting MMP1 and MMP12 using in silico studies supported by experimental screening using LC-MS/MS quadrupole-time of flight (QTOF). Methods: Compounds in propolis were screened using LC-MS/MS QTOF. The 3D structure of all compounds in propolis and protein targets was prepared in Autodock and Biovia Discovery Studio. The molecular docking of all compounds in propolis was carried out using Autodock on PyRx 0.9. Drug-likeness and ADMET analysis of selected compounds in propolis with the lowest affinity were observed. Lastly, molecular dynamic simulations of the best compounds in propolis were conducted using the GROMACS 2020 package. Results: Eleven flavonoid and phenolic compounds were identified in propolis using LC-MS/MS QTOF analysis. Molecular docking simulations showed that licoflavone A and pinostrobin exhibited the lowest binding affinity to MMP1 and MMP12, respectively. Molecular dynamic simulations revealed that licoflavone A formed a more stabilized complex with MMP1, while pinostrobin formed a more stabilized complex with MMP12 than the native ligand. Conclusions: This study revealed new candidates for MMP1 and MMP12 inhibitors from propolis compounds that can enhance wound healing. It is hoped that the evidence gathered in this study provides crucial new information in exploring new wound-healing medications.


  • Open Access

    New insights of propolis nanoformulation and its therapeutic potential in human diseases

    by Paula Mariana Kustiawan, Putri Hawa Syaifie, Khalish Arsy Al Khairy Siregar, Delfritama Ibadillah, Etik Mardliyati

    Background and purpose: Scientific research is crucial to develop therapies for various disease severity levels, as modern drugs cause side effects and are difficult to predict. Researchers are exploring herbal alternatives with fewer side effects, particularly propolis, which has been validated through in vitro, in vivo, and clinical studies. This will focus on scientific evidence and its supporting technology for developing new bioactive compounds for chronic diseases. Nanotechnology can improve the delivery and absorption of herbal medicines, which often have poor bioavailability due to their high molecular weight and solubility in water, particularly in oral medicines. This technology can enhance propolis's effects through multi-target therapy and reduce side effects. Experimental approach: All publications related to each section of this review were discovered using the search engines Google Scholar, Scopus, and Pubmed. This was only available for publication between 2013 and 2023. The selected publications were used as references in this review after being thoroughly studied. Key results: Evaluation of propolis active compounds, the classification of propolis nano formulations, design concepts, and mechanisms of action of propolis nano formulation. Additionally, the challenges and prospects for how these insights can be translated into clinical benefits are discussed. Conclusion: In the last ten years, a list of nanoformulation propolis has been reported. This review concludes the difficulties encountered in developing large-scale nanoformulations. To commercialize them, improvements in nano carrier synthesis, standardized evaluation methodology within the framework of strategy process improvement, and Good Manufacturing Practices would be required.


  • Revealing curcumin therapeutic targets on SRC, PPARG, MAPK8 and HSP90 as liver cirrhosis therapy based on comprehensive bioinformatic study

    by Khalish Arsy Al Khairy Siregar, Putri Hawa Syaifie, Muhammad Miftah Jauhar, Adzani Gaisani Arda, Nurul Taufiqu Rochman, Paula Mariana Kustiawan, Etik Mardliyati

    Cirrhosis naturally progresses through three stages: compensated, decompensated, and late decompensated, which carry an elevated risk of death. Although curcumin's anti-cirrhosis effects have been studied, underlying mechanism in preventing cirrhosis progression and the correlation between curcumin's action with upregulated genes remains insufficiently explored. In this study, we employed network pharmacology approach to construct a drug-target-disease network through bioinformatics and validate the findings with molecular docking and dynamic simulation. The curcumin-targeted liver cirrhosis network encompassed 54 nodes with 282 edges in protein-protein interactions (PPI) network. By utilizing network centrality analysis, we identified eight crucial genes. KEGG enrichment pathway revealed that these crucial genes are involved in pathway of cancer, endocrine resistance, estrogen signaling, chemical carcinogenesis-receptor activation, lipid metabolism, and atherosclerosis. Notably, these eight genes predominantly participate in cancer-related pathways. Further investigation revealed upregulation of four genes and downregulation of four others in hepatocellular carcinoma patients. These upregulated genes-MAPK8, SRC, PPARG, and HSP90AA1-strongly correlated with reduced survival probability in liver hepatocellular carcinoma patients with survival times approximately under 4000 days (∼11 years). Molecular docking and molecular dynamic results exhibited curcumin's superior binding affinities and stability compared to native ligands of MAPK8, SRC, PPARG, and HSP90AA1 within 50 ns simulations. Moreover, MM-GBSA analysis showed stronger binding energy of curcumin to MAPK8, SRC, and HSP90AA1 than native ligand. In conclusion, this study provides valuable insights into curcumin's potential mechanisms in preventing liver cirrhosis progression, specifically in HCC. These findings offer a theoretical basis for further pharmacological research into anti-HCC effect of curcumin.Communicated by Ramaswamy H. Sarma.


  • Open Access

    Antibody-labelled gold nanoparticles synthesized by laser ablation to detect SARS-CoV-2 antigen spike

    by Asri Sulfianti, Vidhia Tiara Sopandi, Isnaeni Isnaeni, Jodi Suryanggono, Sabar Pambudi, Sjaikhurrizal El Muttaqien, Febby Nurdiya Ningsih, Tika Widayanti, Etik Mardliyati, Annisa Annisa

    Background and purpose: Rapid detection test via lateral flow immunoassay (LFIA) is employed as an alternate method to detect Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection. Gold nanoparticles (AuNPs), a vital component of LFIA, can be synthesized by laser ablation technique. This intense laser radiation may result in monodisperse gold nanoclusters, which are impurity-free and demonstrate innovative biocompatible surface chemistry. In this current research, laser-ablated AuNPs are produced and coupled with an anti-spike SARS-CoV-2 monoclonal antibody (mAb) generated in our prior study. Experimental approach: The AuNPs from 30,000 shots of laser ablation exhibited a robust red color with a maximum absorbance peak at 520 nm. The performance of AuNPs-mAb conjugates as a signal reporter was then evaluated in half-stick LFIA. Key results: The size distribution of AuNPs shows a relatively monodisperse and unimodal distribution with average particle diameters of 44.77 nm and a surface potential of -38.5 mV. The purified anti-spike mAb SARS-CoV-2 yielded two protein bands, representing the mAb heavy chain at 55 kDa and its light chain at 25 kDa. The immobilization of anti-spike mAb onto the surface of AuNPs revealed that 25 g/ml of mAb at phosphate buffer pH 9 was required to stabilize the AuNPs. The functional test of this conjugate was performed using dipstick LFIA, and the result shows that the AuNPs-mAb conjugates could successfully detect commercial spike antigen of SARS-CoV-2 at 10 ng level. Conclusion: In this study, laser-ablated AuNPs were functionalized with anti-spike mAb SARS-CoV-2 and successfully used as a signal reporter in half-stick LFIA for detecting antigen spike SARS-CoV-2.